EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Arrowhead Pharmaceuticals's enterprise value is $2,638.9 Mil.
Arrowhead Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $181.7 Mil. Therefore, Arrowhead Pharmaceuticals's EV-to-Revenue for today is 14.52.
The historical rank and industry rank for Arrowhead Pharmaceuticals's EV-to-Revenue or its related term are showing as below:
ARWR'
s EV-to-Revenue Range Over the Past 10 Years
Min: -17.01 Med: 39.22 Max: 4865.36
Current: 14.52
During the past 13 years, the highest EV-to-Revenue of Arrowhead Pharmaceuticals was 4865.36. The lowest was -17.01. And the median was 39.22.
ARWR's EV-to-Revenue is ranked worse than 63.7% of 1033
companies
in the Biotechnology industry
Industry Median: 7.66
vs ARWR: 14.52
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Arrowhead Pharmaceuticals's EV-to-Revenue
For the Biotechnology subindustry, Arrowhead Pharmaceuticals's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arrowhead Pharmaceuticals's EV-to-Revenue Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Arrowhead Pharmaceuticals's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Arrowhead Pharmaceuticals's EV-to-Revenue falls into.
Arrowhead Pharmaceuticals's current Enterprise Value is $2,638.9 Mil.
Arrowhead Pharmaceuticals's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $181.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arrowhead Pharmaceuticals's share price for today is $22.12.
Arrowhead Pharmaceuticals's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.68.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arrowhead Pharmaceuticals EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Arrowhead Pharmaceuticals's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Arrowhead Pharmaceuticals (Arrowhead Pharmaceuticals) Business Description
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ARWR has been successfully added to your 